Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: A report from the children's oncology group study AHOD0031

Journal of Clinical Oncology

Volumn 32, Issue 32, 2014, Pages 3651-3658

  Friedman, Debra L ^a   Chen, Lu ^a   Wolden, Suzanne ^c   Buxton, Allen ^b   McCarten, Kathleen ^f   FitzGerald, Thomas J ^f   Kessel, Sandra ^f   De Alarcon, Pedro A ^g   Chen, Allen R ^b,h   Kobrinsky, Nathan ⁱ   Ehrlich, Peter ^j   Hutchison, Robert E ^d   Constine, Louis S ^e   Schwartz, Cindy L ^k  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

^e UNIVERSITY OF ROCHESTER   (United States)

^f Quality Assurance Review Center   (United States)

^g UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ MeritCare Roger Maris Cancer Center   (United States)

^j UNIVERSITY OF MICHIGAN   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ARTICLE; BASAL CELL CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANDIDEMIA; CAUSE OF DEATH; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRAM NEGATIVE SEPSIS; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; INFANT; INTERMEDIATE RISK PATIENT; INVOLVED FIELD RADIATION THERAPY; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYCOSIS FUNGOIDES; MYELODYSPLASTIC SYNDROME; NEWBORN; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SYNOVIAL SARCOMA; TESTIS CANCER; THYROID CANCER; TRAFFIC ACCIDENT; TREATMENT RESPONSE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; PATHOLOGY; PRESCHOOL CHILD; REMISSION; RISK FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PREDNISONE; REMISSION INDUCTION; RISK FACTORS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84911866817     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.5410     Document Type: Article

References (39)

1. Howlader N, Noone AM, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), Bethesda, MD, National Cancer Institute, 2012. http://seer.cancer.gov/csr/1975-2009-pops09
2. Armstrong GT, Liu Q, Yasui Y, et al: Late mortality among 5-year survivors of childhood cancer: A summary from the Childhood Cancer Survivor Study. J Clin Oncol 27:2328-2338, 2009
3. Bhatia S, Yasui Y, Robison LL, et al: High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the Late Effects Study Group. J Clin Oncol 21:4386-4394, 2003
4. Castellino SM, Geiger AM, Mertens AC, et al: Morbidity and mortality in long-term survivors of Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study. Blood 117:1806-1816, 2011
5. Constine LS, Tarbell N, Hudson MM, et al: Subsequent malignancies in children treated for Hodgkin's disease: Associations with gender and radiation dose. Int J Radiat Oncol Biol Physics 72:24-33, 2008
6. Friedman DL, Constine LS: Late effects of treatment for Hodgkin lymphoma. J Natl Compr Cancer Netw 4:249-257, 2006
7. Mertens AC, Yasui Y, Liu Y, et al: Pulmonary complications in survivors of childhood and adolescent cancer: A report from the Childhood Cancer Survivor Study. Cancer 95:2431-2441, 2002
8. O'Brien MM, Donaldson SS, Balise RR, Whittemore AS, and Link MP: Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol 28:1232-1239, 2010
9. Schellong G, Riepenhausen M, Bruch C, et al: Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 55:1145-1152, 2010
10. Sklar C, Whitton J, Mertens A, et al: Abnormalities of the thyroid in survivors of Hodgkin's disease: Data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 85:3227-3232, 2000
11. Sklar CA, Mertens AC, Mitby P, et al: Premature menopause in survivors of childhood cancer: A report from the childhood cancer survivor study. J Natl Canc Inst 98:890-896, 2006
12. Schwartz CL, Constine LS, Villaluna D, et al: A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and highrisk Hodgkin lymphoma: The results of P9425. Blood, 114:2051-2059, 2009
13. Donaldson SS, Link MP, Weinstein HJ, et al: Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 25:332-337, 2007
14. Dörffel W, Lüders H, Rühl U, et al: Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: Analysis and outlook. Klin Padiatr 215:139-145, 2003
15. Hutchinson RJ, Fryer CJ, Davis PC, et al: MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: Results of the Children's Cancer Group Phase III Trial. J Clin Oncol 16:897-906, 1998
16. Kelly KM, Sposto R, Hutchinson R, et al: BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: A report from the Children's Oncology Group. Blood, 117:2596-2603, 2011
17. Kung FH, Schwartz CL, Ferree CR, et al: POG 8625: A randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA1 Hodgkin Disease: A report from the Children's Oncology Group. J Pediatr Hematol Oncol 28:362-368, 2006
18. Nachman JB, Sposto R, Herzog P, et al: Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20:3765-3771, 2002
19. Friedmann AM, Hudson MM, Weinstein HJ, et al: Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. J Clin Oncol 20:3088-3094, 2002
20. Wolden SL, Chen L, Kelly KM, et al: Longterm results of CCG 5942: A randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's Lymphoma-A report from the Children's Oncology Group. J Clin Oncol 30:3174-3180, 2012
21. Dieckmann K, Pötter R, Hofmann J, et al: Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90. Int J Radiat Oncol Biol Phys 56:644-652, 2003
22. Fryer CJ, Hutchinson RJ, Krailo M, et al: Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: A report from the Children's Cancer Study Group. J Clin Oncol 8:1971-1980, 1990
23. Mauz-Körholz C, Hasenclever D, Dörffel W, et al: Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: The GPOH-HD-2002 study. J Clin Oncol 28:3680-3686, 2010
24. Tebbi CK, Mendenhall NP, London WB, et al: Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology Group. Pediatr Blood Cancer 59:1259-1265, 2012
25. Weiner MA, Leventhal B, Brecher ML, et al: Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol 15:2769-2779, 1997
26. Carde P, Koscielny S, Franklin J, et al: Early response to chemotherapy: A surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol 13:86-91, 2002(suppl 1)
27. Metzger ML, Weinstein HJ, Hudson MM, et al: Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA 307:2609-2616, 2012
28. Lister TA, Crowther D, Sutcliffe SB, et al: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989
29. Lan KKG, De Mets DL: Discrete sequential boundaries for clinical trials. Biometrika 70:659-663, 1983
30. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
31. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley & Sons, 1980
32. Weiner MA, Leventhal BG, Marcus R, et al: Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol 9:1591-1598, 1991
33. Advani R, Maeda L, Lavori P, et al: Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol 25:3902-3907, 2007
34. Gallamini A, Hutchings M, Rigacci L, et al: Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007
35. Gallamini A, O'Doherty M, Report of satellite workshop on interim-PET in Hodgkin lymphoma:8th International Symposium on Hodgkin Lymphoma, Cologne, 23 October 2010. Leuk Lymphoma 52:583-586, 2011
36. Kobe C, Dietlein M, Franklin J, et al: Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112:3989-3994, 2008
37. Yeh JM, Diller L. Pediatric Hodgkin lymphoma: Trade-offs between short- and long-term mortality risks. Blood 120:2195-2202, 2012
38. Smith MA, Rubinstein L, Anderson JR, et al: Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 17:569-577, 1999
39. Sieber M, Tesch H, Pfistner B, et al: Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: Final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol 15:276-282, 2004